Equities
Health CareMedical Equipment and Services
  • Price (USD)16.00
  • Today's Change-0.127 / -0.79%
  • Shares traded26.40k
  • 1 Year change+9.16%
  • Beta0.7888
Data delayed at least 15 minutes, as of Nov 21 2024 18:40 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Olympus Corp is a Japan-based company mainly engaged in the manufacture and sale of endoscopes, therapeutic equipment, scientific and other products. The Company operates through three business segments. The Endoscope segment provides gastrointestinal endoscopes, surgical endoscopes, and medical services. The Therapeutic Equipment segment provides gastrointestinal treatment instruments, urology products, respiratory products, energy devices, otolaryngology products and gynecology products. The Others segment provides biomaterials and orthopedic instruments. The Company is also engaged in the business activities, including holding companies and financial investments related to each business.

  • Revenue in USD (TTM)6.26bn
  • Net income in USD564.41m
  • Incorporated1919
  • Employees28.84k
  • Location
    Olympus Corp2951, Ishikawa-machiHACHIOJI-SHI 192-8507JapanJPN
  • Phone+81 426422111
  • Fax+81 333402062
  • Websitehttps://www.olympus.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Solventum Corp8.22bn720.00m11.81bn22.01k16.423.709.341.444.164.1647.4518.480.58313.937.19373,290.305.11--6.03--56.38--8.76--0.82685.020.7176--0.8241--0.2234------
Globus Medical Inc2.48bn91.51m13.26bn5.00k125.962.7937.905.350.66360.663618.0829.940.47471.284.58495,719.201.756.901.997.4558.1471.733.6914.051.64--0.09740.0053.3417.08-35.39-4.725.57--
Revvity Inc2.72bn258.26m13.55bn11.50k53.151.7219.734.982.092.0622.0664.880.20782.894.37236,657.001.974.762.155.3955.4457.199.4915.342.9711.960.28696.52-16.95-0.1982-64.99-5.28-2.690.00
Avantor Inc6.82bn309.60m13.71bn14.50k44.332.4719.182.010.45440.454410.018.160.5325.566.09470,331.002.422.972.753.3533.5333.444.545.061.063.290.46980.00-7.263.51-51.52--31.17--
Baxter International Inc11.77bn225.00m16.65bn60.00k73.822.1212.701.410.4420.21423.1015.420.41052.915.42196,133.300.81980.19421.050.233338.4338.202.000.36741.093.810.61961,398.942.125.9497.15--0.9829.71
Align Technology, Inc.3.96bn441.57m16.71bn21.61k38.164.2428.714.225.875.8752.6352.760.62454.324.14183,272.506.9616.3410.3924.1469.9871.7211.1523.161.14--0.000.003.4214.4523.092.15-4.46--
Hologic Inc4.03bn789.50m18.13bn6.99k23.503.5316.504.503.323.3216.9722.090.44062.726.57--8.6313.129.8415.2056.2560.8219.5924.753.0364.450.3307---0.00253.6673.14--4.30--
Insulet Corp1.98bn420.90m18.70bn3.00k46.3416.7237.479.435.755.7525.9615.940.72231.426.14661,300.0015.322.7118.563.1469.3665.8121.224.282.8098.710.55570.0030.0224.664,384.78128.77-7.63--
Olympus Corp - ADR6.26bn564.41m19.17bn28.84k33.454.0819.373.060.48230.41395.343.950.65251.695.76217,209.305.88--8.19--67.75--9.01--1.1240.320.2588--6.16---80.69------
Cooper Companies Inc3.80bn359.30m19.73bn15.00k55.182.4926.815.191.801.8019.0239.800.31961.705.56253,606.703.0210.063.2911.3466.3665.549.4529.001.185.460.24930.34698.617.24-23.74-3.6615.180.00
Illumina Inc4.39bn-1.58bn20.88bn10.59k--9.85--4.76-10.00-10.0027.6113.360.54412.666.17414,542.00-19.63-6.20-23.16-7.2863.9466.39-36.08-15.481.8538.440.4834---1.756.2173.64---7.91--
Steris PLC5.12bn602.62m20.95bn18.18k34.933.1818.924.096.084.3851.6266.800.47583.865.49281,655.405.625.196.105.6843.0143.6411.8110.971.558.290.252836.5613.2813.06-1.0712.6713.698.83
Waters Corp2.91bn622.64m21.24bn7.90k34.1413.2526.077.3110.4810.4848.8927.000.6452.204.47367,740.1013.8219.7716.7225.2959.7358.4521.4323.381.3810.110.53250.00-0.52294.09-9.261.534.72--
Zimmer Biomet Holdings Inc7.60bn1.08bn21.75bn18.00k20.811.7610.572.865.255.2536.8762.000.35380.91365.38421,972.205.052.215.822.5271.7871.2514.287.280.69877.520.342538.906.55-1.40252.86--9.440.00
West Pharmaceutical Services Inc.2.88bn499.60m22.57bn10.60k46.188.2135.597.856.756.7538.8637.960.77434.505.51271,358.5013.0215.6115.1618.6534.8738.0616.8118.472.23--0.069510.692.1811.432.2823.7628.166.20
Data as of Nov 21 2024. Currency figures normalised to Olympus Corp's reporting currency: US Dollar USD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Swiss Life Asset Management AGas of 30 Jun 20249.96k0.00%
RhumbLine Advisers LPas of 30 Sep 20249.55k0.00%
GAMMA Investing LLCas of 30 Sep 20242.69k0.00%
Ramirez Asset Management, Inc.as of 30 Sep 20242.59k0.00%
Nikko Asset Management Asia Ltd.as of 30 Jun 2024500.000.00%
PNC Investments LLCas of 30 Sep 202485.000.00%
More ▼
Data from 30 Sep 2024 - 15 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.